Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project.

Meurer WJ, Legocki L, Mawocha S, Frederiksen SM, Guetterman TC, Barsan W, Lewis R, Berry D, Fetters M.

Trials. 2016 Jul 29;17:373. doi: 10.1186/s13063-016-1493-z.

2.

Protocol Deviations before and after Treatment with Intravenous Tissue Plasminogen Activator in Community Hospitals.

Adelman EE, Scott PA, Skolarus LE, Fox AK, Frederiksen SM, Meurer WJ.

J Stroke Cerebrovasc Dis. 2016 Jan;25(1):67-73. doi: 10.1016/j.jstrokecerebrovasdis.2015.08.036. Epub 2015 Sep 26.

PMID:
26419527
3.

Prevention of emergency physician migratory contamination in a cluster randomized trial to increase tissue plasminogen activator use in stroke (the INSTINCT trial).

Weston VC, Meurer WJ, Frederiksen SM, Fox AK, Scott PA.

Am J Emerg Med. 2014 Dec;32(12):1460-3. doi: 10.1016/j.ajem.2014.08.073. Epub 2014 Sep 6.

4.

The impact of emergency physician turnover on planning for prospective clinical trials.

Meurer WJ, Sozener CB, Xu Z, Frederiksen SM, Kade AM, Olgren M, Vieder SJ, Kalbfleish JD, Scott PA.

West J Emerg Med. 2013 Feb;14(1):16-22. doi: 10.5811/westjem.2011.8.6798.

5.

Does preexisting antiplatelet treatment influence postthrombolysis intracranial hemorrhage in community-treated ischemic stroke patients? An observational study.

Meurer WJ, Kwok H, Skolarus LE, Adelman EE, Kade AM, Kalbfleisch J, Frederiksen SM, Scott PA.

Acad Emerg Med. 2013 Feb;20(2):146-54. doi: 10.1111/acem.12077.

6.

A multilevel intervention to increase community hospital use of alteplase for acute stroke (INSTINCT): a cluster-randomised controlled trial.

Scott PA, Meurer WJ, Frederiksen SM, Kalbfleisch JD, Xu Z, Haan MN, Silbergleit R, Morgenstern LB; INSTINCT Investigators.

Lancet Neurol. 2013 Feb;12(2):139-48. doi: 10.1016/S1474-4422(12)70311-3. Epub 2012 Dec 21.

7.

Antihypertensive treatment prolongs tissue plasminogen activator door-to-treatment time: secondary analysis of the INSTINCT trial.

Skolarus LE, Scott PA, Burke JF, Adelman EE, Frederiksen SM, Kade AM, Kalbfleisch JD, Ford AL, Meurer WJ.

Stroke. 2012 Dec;43(12):3392-4. doi: 10.1161/STROKEAHA.112.662684. Epub 2012 Oct 2.

8.

Provider perceptions of barriers to the emergency use of tPA for acute ischemic stroke: a qualitative study.

Meurer WJ, Majersik JJ, Frederiksen SM, Kade AM, Sandretto AM, Scott PA.

BMC Emerg Med. 2011 May 6;11:5. doi: 10.1186/1471-227X-11-5.

9.

Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams.

Scott PA, Frederiksen SM, Kalbfleisch JD, Xu Z, Meurer WJ, Caveney AF, Sandretto A, Holden AB, Haan MN, Hoeffner EG, Ansari SA, Lambert DP, Jaggi M, Barsan WG, Silbergleit R.

Acad Emerg Med. 2010 Oct;17(10):1062-71. doi: 10.1111/j.1553-2712.2010.00868.x.

10.

Attitudes and beliefs of Michigan emergency physicians toward tissue plasminogen activator use in stroke: baseline survey results from the INcreasing Stroke Treatment through INteractive behavioral Change Tactic (INSTINCT) trial hospitals.

Scott PA, Xu Z, Meurer WJ, Frederiksen SM, Haan MN, Westfall MW, Kothari SU, Morgenstern LB, Kalbfleisch JD.

Stroke. 2010 Sep;41(9):2026-32. doi: 10.1161/STROKEAHA.110.581942. Epub 2010 Aug 12.

11.

Lack of association between pretreatment neurology consultation and subsequent protocol deviation in tissue plasminogen activator-treated patients with stroke.

Meurer WJ, Caveney AF, Lo A, Zhang L, Frederiksen SM, Sandretto AM, Silbergleit R, Scott PA.

Stroke. 2010 Sep;41(9):2098-101. doi: 10.1161/STROKEAHA.110.588491. Epub 2010 Aug 5.

12.

Lack of association between hyperglycaemia at arrival and clinical outcomes in acute stroke patients treated with tissue plasminogen activator.

Meurer WJ, Scott PA, Caveney AF, Majersik JJ, Frederiksen SM, Sandretto A, Holden AB, Silbergleit R.

Int J Stroke. 2010 Jun;5(3):163-6. doi: 10.1111/j.1747-4949.2010.00425.x.

13.

Qualitative data collection and analysis methods: the INSTINCT trial.

Meurer WJ, Frederiksen SM, Majersik JJ, Zhang L, Sandretto A, Scott PA.

Acad Emerg Med. 2007 Nov;14(11):1064-71. Epub 2007 Jul 24.

14.
15.

The feasibility of pain assessment in the prehospital setting.

McLean SA, Domeier RM, DeVore HK, Hill EM, Maio RF, Frederiksen SM.

Prehosp Emerg Care. 2004 Apr-Jun;8(2):155-61.

PMID:
15060849
16.

Prevalence of atrial fibrillation and antithrombotic prophylaxis in emergency department patients.

Scott PA, Pancioli AM, Davis LA, Frederiksen SM, Eckman J.

Stroke. 2002 Nov;33(11):2664-9.

17.

Multicenter prospective validation of prehospital clinical spinal clearance criteria.

Domeier RM, Swor RA, Evans RW, Hancock JB, Fales W, Krohmer J, Frederiksen SM, Rivera-Rivera EJ, Schork MA.

J Trauma. 2002 Oct;53(4):744-50.

PMID:
12394877
18.

Patient preferences regarding pain medication in the ED.

Beel TL, Mitchiner JC, Frederiksen SM, McCormick J.

Am J Emerg Med. 2000 Jul;18(4):376-80.

PMID:
10919522
19.

Conversion of the iridoid glucoside antirrhinoside into 3-azabicyclo[3.3.0]octane building blocks.

Franzyk H, Frederiksen SM, Jensen SR.

J Nat Prod. 2000 May;63(5):592-5.

PMID:
10843565
20.

The reliability of prehospital clinical evaluation for potential spinal injury is not affected by the mechanism of injury.

Domeier RM, Evans RW, Swor RA, Hancock JB, Fales W, Krohmer J, Frederiksen SM, Shork MA.

Prehosp Emerg Care. 1999 Oct-Dec;3(4):332-7.

PMID:
10534035
Items per page

Supplemental Content

Loading ...
Write to the Help Desk